10th week of 2016 patent applcation highlights part 9 |
Patent application number | Title | Published |
20160067302 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors are disclosed having the general formula: | 2016-03-10 |
20160067303 | ROMIDEPSIN FORMULATIONS AND USES THEREOF - Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer. | 2016-03-10 |
20160067304 | ROMIDEPSIN FORMULATIONS AND USES THEREOF - Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer. | 2016-03-10 |
20160067305 | Lamin A, An Activator of Longevity/Anti-Aging SIRT1 Protein - In one embodiment, the present invention provides methods of modulating the deacetylase activity of SIRT1 in one or more cell by modifying the binding affinity of lamin A to SIRT1 via one or more interaction modifying compound. In another embodiment, the present invention provides methods of screening SIRT1-activating/inhibiting compounds based on the interaction between lamin A and SIRT1 proteins and SIRT1-activating property of lamin A. In another embodiment, the present invention provides uses of SIRT1-activating compounds to treat patient(s) suffering from metabolic and/or aging-related degenerative diseases, and uses of SIRT1-inhibiting compounds to treat human malignancies. | 2016-03-10 |
20160067306 | TREATMENT AGENT FOR COGNITIVE IMPAIRMENT INDUCED BY AMYLOID BETA-PROTEIN, THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE, AND TREATMENT METHOD AND PATHOLOGICAL ANALYSIS METHOD RELATED TO THESE - The present invention aims to provide an anti-Alzheimer's disease agent based on an action mechanism associated with amyloid β protein, which action mechanism is different from conventional action mechanisms. The therapeutic drug for Alzheimer's disease according to the present invention contains a therapeutic agent for cognitive impairment induced by amyloid β protein, which therapeutic agent comprises a peptide having the amino acid sequence represented by SEQ ID NO:1 or a peptide similar to this peptide, especially a peptide containing the amino acid sequence represented by SEQ ID NO:2, which is a partial sequence of SEQ ID NO:1. | 2016-03-10 |
20160067307 | METHODS OF TREATING CANCER - Methods of treating cancers comprising FGFR1 gene amplification, FGFR1 overexpression, FGFR3 overexpression, FGFR3 amplification, FGF2 overexpression, and/or FGF2 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent. In some embodiments, methods of treating cancers comprising administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one chemotherapeutic agent are provided. | 2016-03-10 |
20160067308 | USE OF HUMAN SMALL LEUCINE ZIPPER PROTEIN IN OSTEOGENESIS PROCEDURE - The present invention relates to a use of a human small leucine zipper protein in the osteogenesis procedure. More specifically, sLZIP increases the transcriptional activity of Runx2 and inhibits the transcriptional activity of PPARγ2, thereby increasing the osteoblast differentiation, so that sLZIP performs an important role in the osteogenesis procedure, and thus can be used as a marker for treating bone disease and developing new medicines. | 2016-03-10 |
20160067309 | COMPOSITION FOR REGENERATION OF CARTILAGE - A novel composition for regenerating a cartilage has been demanded, which can achieve a good effect of regenerating a hyaline cartilage that is a nearly normal cartilage without requiring the use of any transplanted cell. The present invention provides a composition for regenerating a cartilage, wherein (a) a monovalent metal salt of low endotoxin alginic acid and (b) SDF-1 are used in combination. | 2016-03-10 |
20160067310 | Compositions and Methods for the Systemic Treatment of Arthritis - The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β. | 2016-03-10 |
20160067311 | USE OF ELSIGLUTIDE TO TREAT GASTROINTESTINAL MUCOSITIS INCLUDING CHEMOTHERAPY-INDUCED DIARRHEA - The invention relates to the use of elsiglutide to prevent or reduce the occurrence of gastrointestinal damage caused by chemotherapeutic agents, including gastrointestinal mucositis and chemotherapy-induced diarrhea (CID). | 2016-03-10 |
20160067312 | GENE THERAPY FOR AMYOTROPHIC LATERAL SCLEROSIS AND OTHER SPINAL CORD DISORDERS - This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention a transgene product is delivered to a subject's spinal cord by administering a recombinant neurotrophic viral vector containing the transgene to the brain. The viral vector delivers the transgene to a region of the brain which is susceptible to infection by the virus and which expresses the encoded recombinant viral gene product. Also provided are compositions for delivery of a transgene product to a subject's spinal cord by administering a recombinant neurotrophic viral vector containing the transgene to the subject's brain. | 2016-03-10 |
20160067313 | ASSESSMENT OF CARDIAC HEALTH AND THROMBOTIC RISK IN A PATIENT - The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis. | 2016-03-10 |
20160067314 | COMPOSITIONS AND METHODS FOR INHIBITING CHEMORESISTANCE IN CANCER AND IMPROVING RESPONSE TO THERAPY - Metastatic melanomas are highly resistant to radiation and chemotherapy from the earliest stages, which is a major factor in poor clinical outcomes. Activated leukocyte adhesion molecule (ALCAM)/CD166 was the gene that showed the highest correlation with detachment-induced chemoresistance. SiRNA-mediated depletion or antibody blocking of ALCAM specifically inhibited the increase in chemoresistance after detachment. This antibody also improved chemotherapeutic responses in a mouse xenograft model of human melanoma. Previous studies identified ALCAM as a marker for tumor aggressiveness and poor prognosis, and as a marker for “stemness”. Targeting ALCAM may therefore represent a novel approach for treatment of otherwise intractable melanomas. It was also found that stimulating integrin signaling enhanced chemosensitivity of melanoma to chemotherapeutic agents. The present invention provides a novel multimeric peptide construct comprising fibronectin fragments useful for stimulating integrin signaling and for enhancing chemosensitivity of melanomas. | 2016-03-10 |
20160067315 | INHIBITOR OF EXTRACELLULAR TRAP FORMATION IN LEUKOCYTES - The present invention has an object of providing a novel drug inhibiting formation of leukocyte extracellular traps. The present invention provides a lactoferrin-containing inhibitor of formation of leukocyte extracellular traps, and a lactoferrin-containing composition for treating a disease associated with the formation of the leukocyte extracellular traps. | 2016-03-10 |
20160067316 | Selective Sensitization of Cancer Cells to, and Selective Protection of Non-Cancer Cells from Genotoxic Therapies - Compositions and methods are disclosed that employ Tousled-like kinase to selectively protect normal tissues from the adverse effects of radiation therapy, genotoxic chemotherapy and the like without protecting cancer tissues; or to sensitize cancer cells to such cancer therapies without similarly sensitizing normal tissues; or both protect normal cells and sensitize cancer cells. The compositions and methods may be used as a complementary therapy to selectively reduce adverse effects of the principal therapy (radiation therapy or chemotherapy) in normal tissues, with minimal impact on the antitumor effects of the principal therapy. | 2016-03-10 |
20160067317 | METHODS OF TREATING PULMONARY SARCOIDOSIS - Methods of treating pulmonary sarcoidosis are described herein. Patients in need of treatment for pulmonary sarcoidosis are administered a therapeutically effective amount of a mucolytic agent such as DNase I. In some embodiments, the DNase I is a recombinant human DNase I such as dornase alfa. | 2016-03-10 |
20160067318 | FREE-STANDING BIODEGRADABLE PATCH - Methods and apparatus for a free-standing biodegradable patch suitable for medical applications, especially intravascular, minimally invasive and intraoperative surgical applications are provided, wherein the patch comprises a free-standing film or device having a mixture of a solid fibrinogen component and a solid thrombin component that, when exposed to an aqueous environment, undergoes polymerization to form fibrin. In alternative embodiments the patch may comprise a solid fibrinogen component, with or without an inorganic calcium salt component. The patch may take a non-adherent form during delivery to a target location within a vessel or tissue, and thereafter may be activated to adhere to vessel wall or tissue, and may include a number of additives, including materials to improve the mechanical properties of the patch, or one or more therapeutic or contrast agents. | 2016-03-10 |
20160067319 | METHOD FOR TREATING PREMATURE EJACULATION WITH A BOTULINUM NEUROTOXIN - Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a Clostridial neurotoxin, such a botulinum neurotoxin, to the patient, are provided. | 2016-03-10 |
20160067320 | Fungal Immunogens and Related Materials and Methods - The present disclosure provides immunogenic materials and methods useful for reducing the risk of fungal infections, particularly valley fever. The disclosure also provides assays for identifying compounds useful to treat valley fever, as well as methods for ameliorating the symptoms of valley fever. | 2016-03-10 |
20160067321 | METHOD FOR TREATING PANCREATIC CANCER WITH TOXOPLASMA GONDII VACCINE - Attenuated | 2016-03-10 |
20160067322 | METHOD OF TREATING LUNG CANCER BY VACCINATION WITH MUC-1 LIPOPEPTIDE - The invention is directed to the treatment of lung cancer, preferably non-small cell lung cancer (NSCLC) by means of a combination therapy comprising concurrent chemo-radiotherapy followed by vaccination with a muc-1 lipopetide. The therapy elicits prolonged survival rates compared to a respective therapy including sequential chemo-radiotherapy. | 2016-03-10 |
20160067323 | Francisella tularensis Live Vaccine Strains and Methods of Use - The present invention includes live strain of | 2016-03-10 |
20160067324 | NOVEL VACCINE FORMULATION FOR OCULAR IMMUNIZATION - The present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans and animals including mammals and birds. More particularly, it relates to subunit vaccines that are effective against pathogens causing infections thereof for use in humans and animals including mammals and birds. The present invention specifically provides a novel vaccine formulation suitable for ocular immunization comprising a subunit vaccine antigen in an amount to provoke a protective immune response and at least two adjuvants of which one is corpuscular. It further provides a method for inducing a local and systemic immune response and methods for preventing recurrence of ocular infections and/or modulates the occurrence and/or severity of sequels. | 2016-03-10 |
20160067325 | Purification of Polysaccharide Protein Conjugates - The invention describes a method of purifying polysaccharide protein conjugates using mixed mode chromatography. The method involves contacting a crude polysaccharide protein conjugate with a mixed mode resin comprising an inert porous shell and an activated core under conditions of low conductivity that allow binding of the contaminants and collecting the unbound polysaccharide protein conjugate in a flowthrough. | 2016-03-10 |
20160067326 | MUTANT BACTERIA FOR PRODUCTION OF GENERALIZED MODULES FOR MRMBRANE ANTIGENS - Gram-negative bacterial strains are generated by inactivating at least one LytM catalytic domain-containing protein, such as NT013, NT017 and NT022 of non typeable | 2016-03-10 |
20160067327 | OMV VACCINES - The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of | 2016-03-10 |
20160067328 | RECOMBINANT NEURAMINIDASE AND USES THEREOF - A recombinant neuraminidase based on amino acid sequence (SEQ ID NO: 1) of wild-type pH1N1-NA (A/Texas/05/2009) influenza virus is provided. The recombinant neuraminidase of the present invention has an ectodomain with an amino acid sequence essentially identical to SEQ ID NO: 1 and replaced at specific positions 149, 344, 365 and 366 residue(s) with corresponding amino acids of other influenza viruses. The recombinant neuraminidase may incur cross-protective immunity and be used as universal influenza vaccine. | 2016-03-10 |
20160067329 | POLYVALENT VACCINE - The disclosure relates to nucleic acids mosaic clade M HIV-1 Env polypeptides and to compositions and vectors comprising same. The nucleic acids are suitable for use in inducing an immune response to HIV-1 in a human. | 2016-03-10 |
20160067330 | HERPES VIRUS VACCINES AND TREATMENTS - Provided herein are vaccine compositions and methods of their use in treating or preventing Herpes diseases. | 2016-03-10 |
20160067331 | VIRAL PROTEINS AS IMMUNOMODULATORY AGENTS AND VACCINE COMPONENTS - The invention provides compositions and methods involving viral envelope polypeptides and peptides for use in modulating immune responses, including inhibition inflammation related to pathogenic T-cell activation. In addition, modification of the viral sequences responsible for modulating immune response provides for improved vaccine formulations. | 2016-03-10 |
20160067332 | E1E2 HCV VACCINES AND METHODS OF USE - The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1/E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1/E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are useful in carrying out methods of inducing an immune response to HCV. The present disclosure further provides methods of stimulating an immune response to HCV in an individual. | 2016-03-10 |
20160067333 | GENERATING PEPTOID VACCINES - The present invention provides for methods of identifying peptoid mimetics that will mimic B cell epitopes when delivered as vaccine compositions. One aspects of the invention is the use of monoclonal antibody that is broadly protective to select the mimetics, thereby identifying an epitope from a pathogen or other disease-causing agent that will be common among most or all variants of that pathogen or agent. | 2016-03-10 |
20160067334 | Vaccines With Biomolecular Adjuvants - Disclosed herein is a vaccine comprising an antigen and one or more bimolecular adjuvant. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof. | 2016-03-10 |
20160067335 | METHOD FOR IMPROVING THE EFFICACY OF A SURVIVIN VACCINE IN THE TREATMENT OF CANCER - The present invention provides methods for improving the efficacy of a vaccine in the treatment of cancer. The methods of the invention comprise the administration of at least two doses of an agent that interferes with DNA replication prior to vaccination with a survivin vaccine. Also provided are compositions for use in the methods of the invention. | 2016-03-10 |
20160067336 | METHODS FOR TREATING A DISEASE OR DISORDER USING ORAL FORMULATIONS OF CYTIDINE ANALOGS IN COMBINATION WITH AN ANTI-PD1 OR ANTI-PDL1 MONOCLONAL ANTIBODY - The present disclosure provides methods of treating diseases or disorders with oral cytidine analogs (e.g., 5-azacytidine) in combination with anti-PD1/anti-PDL1 antibodies (e.g., pembrolizumab or durvalumab). The diseases or disorders include, but are not limited to, relapsed or refractory myelodysplastic syndromes, acute myeloid leukemia, ovarian cancer, or non-small cell lung cancer. | 2016-03-10 |
20160067337 | COMBINATION OF DR5 AGONIST AND ANTI-PD-1 ANTAGONIST AND METHODS OF USE - Provided are methods and compositions for treating cancer using an effective amount of a PD-1 antagonist (e.g., an antibody) in combination with a DR4 or DR5 agonist (e.g., an antibody). | 2016-03-10 |
20160067338 | METHOD FOR CARRYING THERAPEUTIC SUBSTANCES INTO CELLS - The present invention relates to compositions containing nanoparticies and uses of said composition for transferring therapeutically active substances into cells by means of specifically coated nanoparticles. The chemical design of the particles is such that a large amount thereof is absorbed into the cells. No direct bond between nanoparticle and the therapeutically active substance is required for the transfer into the cells. Thanks to said transfer, an increased efficacy of the substance and simultaneously reduced systemic toxicity is achieved, i.e. an increase in the efficacy while the side effects are reduced. | 2016-03-10 |
20160067339 | COMPOSITIONS COMPRISING APOMORPHINE AND ORGANIC ACIDS AND USES THEREOF - The present invention provides stable liquid or semi-solid pharmaceutical compositions of apomorphine, more particularly compositions comprising apomorphine and an organic acid, which are useful in treatment of neurological or movement diseases or disorders, e.g., Parkinson's disease, or conditions associated therewith. | 2016-03-10 |
20160067340 | SEMI-SOLID CHEWABLE DOSAGE FORM FOR OVER-THE-COUNTER MEDICATIONS AND METHOD FOR PRODUCING SAME - The invention provides a semi-solid chewable dosage form that contains one or more active pharmaceutical ingredients that are generally available as over-the-counter medications including, for example, chlorpheniramine maleate, phenylephrine hydrochloride, guaifenesin, dextromethorphan hydrobromide, loratadine, or a combination thereof. The invention further provides a semi-solid chewable dosage form that contains chlorpheniramine maleate, phenylephrine hydrochloride or a combination thereof, a gelling agent, gelatin, sugar, a polyol, and a pH adjusting agent. The invention further provides a semi-solid chewable dosage form that contains the active pharmaceutical ingredient chlorpheniramine maleate, phenylephrine hydrochloride or a combination thereof, a gelling agent, gelatin, sugar, corn syrup, and a pH adjusting agent. The semi-solid chewable dosage form is useful for administration to individuals to treat symptoms from allergies, colds, congestion, and the like. | 2016-03-10 |
20160067341 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING - Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them. | 2016-03-10 |
20160067342 | PROTEIN DERIVATIZATION TO ENDOW CELL PENETRATION - Methods and reagents for enhancing cellular uptake of a cargo molecule by covalently bonding optionally-substituted fluorenyl groups to the cargo molecules, where cellular uptake includes at least partial uptake into the cytosol. Useful fluorenylation reagents include those of formula: | 2016-03-10 |
20160067343 | CELLULAR HYDRATION COMPOSITIONS - A composition interacts with a biological cell system that includes bioactive molecules with biomolecular surfaces, cellular components and water molecules with a specific density. The composition includes a biologically active component that is constructed to increase an activity of a biological cell system by increasing the hydration of one or more components of that cell system. The biologically active component may include a primary carbohydrate clathrate subcomponent that increases the H-bonded structure of water, and a secondary solute subcomponent. The biologically active component may include an inclusion complex that is made up of a clathrate component and a complex-forming compound. The clathrate subcomponent may include amyloses or cyclodextrins. There is also a beverage and a method that improves cellular hydration in an animal, such as a human. | 2016-03-10 |
20160067344 | COMPOUNDS AND MEDICAL DEVICES ACTIVATED WITH SOLVOPHOBIC LINKERS - The present disclosure relates to compounds and medical devices activated with a solvophobic material functionalized with a first reactive member and methods of making such compounds and devices. | 2016-03-10 |
20160067345 | OLIGOSACCHARIDE CONJUGATES AND METHODS OF USE - There is provided a method of detecting in a sample the presence of an anti-M and/or anti-A and/or anti-C/Y anti-body, the method comprising contacting the sample with a diagnostic conjugate provided according to the invention, comprising an oligosaccharide which comprises at least two units of 4,6-dideoxy-4-acylamido-α-pyranose and comprising at least one -(1-3)-link between adjacent 4,6-dideoxy-4-acylamido-α-pyranose units, in which the carbon at position 5 in the pyranose is linked to an R group, where R is independently selected from —CH | 2016-03-10 |
20160067346 | BRUSH-POLY (GLYCOAMIDOAMINE)-LIPIDS AND USES THEREOF - The present disclosure provides brush-poly(glycoamidoamine)-lipids (PGALs) (e.g., polymers of any one of Formulae (I)-(IV)) and methods of preparing the PGALs. A described PGAL may include poly(glycoamidoamine)-derived moieties (e.g., | 2016-03-10 |
20160067347 | APJ RECEPTOR AGONISTS AND USES THEREOF - The application is directed to APJ receptor agonist analogs having increased stability relative to the wild type apelin-13 and methods of using the agonist analogs. The analogs can be used, inter alia, in cardiac disorders such as heart failure. | 2016-03-10 |
20160067348 | METHOD OF PREVENTING AND TREATING TYPE 1 DIABETES, ALLOGRAFT REJECTION AND LUNG FIBROSIS (BY TARGETING THE ATP/P2X7R AXIS) - The present invention relates to the role of purinergic receptors and ATP in T cell activation and autocrine system signaling. In one embodiment, the present invention provides a method of preventing or treating diabetes by administering a therapeutically effective inhibitor of ATP to a subject. In another embodiment, the present invention provides a method of preventing or treating fibrosis by administering a P2X7R soluble fusion protein. In another embodiment, the present invention provides a method of preventing or treating graft rejection by administering an inhibitor of P2X receptor signaling. | 2016-03-10 |
20160067349 | HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR - Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapies and diagnostic methods for using the antibodies and antibody drug conjugates. | 2016-03-10 |
20160067350 | Drug-Conjugates, Conjugation Methods, and Uses Thereof - In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided. | 2016-03-10 |
20160067351 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES - The present invention provides specific sites for modifying antibodies or antibody fragments by replacing at least one native amino acid in the constant region of a parental antibody or antibody fragment with cysteine, which can be used as a site of attachment for a payload or linker-payload combination. | 2016-03-10 |
20160067352 | Method of Synthesising ADCs Using Affinity Resins - This invention relates to a solid phase method of synthesizing biomolecule-drug conjugates. In particular, this invention relates to a solid phase method of synthesizing antibody-drug conjugates (ADCs). This invention also relates to intermediate methods of producing immobilized, chemically modified biomolecules, e.g. antibodies. The invention also relates to various uses of capture resins and to biomolecule-drug conjugates, intermediate products and compositions prepared by the methods of the invention. | 2016-03-10 |
20160067353 | PROTEIN-POLYMER-DRUG CONJUGATES - A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L | 2016-03-10 |
20160067354 | PREPARATIONS OF GOLD/MESOPOROUS SILICA HYBRID NANOPARITCLE AND APPLICATIONS - Described is a method to fabricate a gold/mesoporous silica hybrid nanoparticle. According to the process, a gold nanoparticle can be conjugated onto the surface of a mesoporous silica nanoparticle to yield a photothermal stable theranostic platform, gold/mesoporous silica hybrid nanoparticle. The nanoparticles can be useful for disease detection, treatment, and monitoring. | 2016-03-10 |
20160067355 | Composition For Delivery Of Genetic Material - The present invention relates to exosomes, loaded with genetic material and methods of producing them and to the use of such exosomes for delivering genetic material in vivo, in particular the use of such exosomes in methods of gene therapy or gene silencing. | 2016-03-10 |
20160067356 | GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES - The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD 16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ,TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells. | 2016-03-10 |
20160067357 | DETECTION OF HIGH RISK DRUSEN - In some aspects, methods of detecting complement activation in vivo, e.g., in an eye, are provided. In some aspects, methods of detecting high risk drusen are provided. In some aspects, presence of one or more high risk drusen in an eye indicates increased likelihood of developing AMD, GA, or advanced AMD or increased likelihood of rapid progression of AMD. In some embodiments, methods comprise detecting drusen containing or in close proximity to complement activation. In some embodiments methods comprise detecting one or more drusen having inflamed endothelium underlying or in close proximity thereto. In some embodiments methods comprise detecting eye-derived extracellular microvesicles, e.g., exosomes, in a body fluid. In some embodiments methods comprise detecting Th17 cells or a Th17 biomarker in a body fluid. In some embodiments the Th17 biomarker is a cytokine. Methods may be applied individually or in any combination. In some embodiments any of the methods further comprises treating a subject at risk of developing AMD, GA, or advanced AMD or at increased likelihood of rapid progression of AMD with a complement inhibitor. In some aspects, agents useful for performing one or more of the methods are described. | 2016-03-10 |
20160067358 | TUMOR SPECIFIC ANITBODY CONJUGATES AND USES THEREFOR - Provided are isolated antibodies, and fragments and derivatives thereof, which bind to tumor antigens. Provided are antibody/nanoparticle conjugates. Also provided are compositions and delivery agents that include the disclosed antibodies, conjugates, fragments and derivatives thereof; cells that produce the same; methods for producing the same; methods of using the same for detecting, targeting, and/or treating tumors and/or metastatic cells derived therefrom and/or tumor stem cells; and methods for predicting the recurrence of cancer in a subject. | 2016-03-10 |
20160067359 | COMPOSITION HAVING DYE AND CONJUGATE OF POLYETHYLENEGLYCOL AND ADDITIVE AND CONTRAST AGENT FOR PHOTOACOUSTIC IMAGING HAVING THE SAME - The present invention provides contrast agents for photoacoustic imaging which exhibit high degrees of accumulation in tumor and low degrees of retention in the blood and can be administered into the blood. The contrast agents for photoacoustic imaging include a conjugate of a dye and a polyethyleneglycol represented by Formula (1), (5), (6), or (7) and an additive represented by Formula (301). | 2016-03-10 |
20160067360 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS - The present application provides for a compound of Formula I, | 2016-03-10 |
20160067361 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER - A method of reducing radiation exposure of a non-cancerous tissue of a patient diagnosed with a cancer includes administering to the patient an agent capable of competing for binding sites on a surface of the non-cancerous tissue, provided that the administration is carried out after a waiting period that follows administration of a compound including a radionuclide to the patient, the compound having affinity for both a cancerous tissue and the non-cancerous tissue, and, further provided that the binding sites have an affinity for both the agent and the compound. | 2016-03-10 |
20160067362 | HELICAL POLYCARBODIIMIDE POLYMERS AND ASSOCIATED IMAGING, DIAGNOSTIC, AND THERAPEUTIC METHODS - Described herein are suspensions of helical polycarbodiimide polymers that ‘cloak’ nanotubes, thereby effecting control over nanotube emission, providing a new mechanism of environmental responsivity, and enabling precise control over sub-cellular localization. The helical polycarbodiimide polymers described herein are water soluble, easily modifiable, and have unique architectures that facilitate their application in radiopharmaceutical delivery and imaging methods, in therapeutics and therapeutic delivery methods, and their use as sensors—both in conjunction with carbon nanotubes, and without nanotubes. | 2016-03-10 |
20160067363 | Sanitizer - A sanitizer for sanitizing various surfaces including hands, hardware, fixtures, appliances, countertops, equipment, utensils and more and more specifically to a chemical-free sanitizer, more specifically to an ozone-free sanitizer and yet more specifically to an electronic sanitizer and yet more specifically to an ion source sanitizer. | 2016-03-10 |
20160067364 | METHOD AND DEVICE FOR DISINFECTING SPACES AND SURFACES - A system for the disinfection of rooms and surfaces including at least one plate which can be associated with a room to be treated and equipped with a memory containing a plurality of identification data of the room and at least one diffuser device including a tank containing a liquid solution and nebulising means associated with the tank and designed to draw out the liquid solution from the tank spraying it in the space. The diffuser device includes a control unit associated with the nebulising means and which can be associated with the plate, designed for receiving from the plate a signal representing identification data of the room and designed for controlling the nebulising means as a function of the signal in such a way as to sanitise the room in an automatic manner. | 2016-03-10 |
20160067365 | SYSTEMS AND METHODS TO MONITOR PROPER DISINFECTION OF NEEDLELESS CONNECTORS - A device and method for disinfecting a needleless connector, the device including a housing comprising a hub rotationally coupled to a motor, the motor being operably connected to a power source, the hub further comprising a receptacle configured to receive a cleaning head, wherein the device is configured to detect achievement of one or more minimum thresholds which are recommended to achieve proper disinfection of the needleless connector. Various devices and methods are further provided to permit tracking and reporting of disinfection events. | 2016-03-10 |
20160067366 | Multi-layered incense device and method of making such - A multi-layered incense device comprising a rigid support layer in a shape of an ornate design or pattern, at least one water settable wood powder layer disposed on each side of the support layer, an aromatic layer disposed on the wood powder layer, and a powdered dye layer disposed on the aromatic layer. The multi-layered device can be produced by cutting a template to form a support layer, moistening the support layer with water and then coating it with a wood powder mixture. The wood powder mixture is sprinkled with water for setting. The support layer and the wood powder mixture is then placed between two layers of vinyl covered screen for curing, and is then sprinkled with water, an aromatic layer and a powdered dye layer. The support layer and its various mixture and layers are placed between two vinyl covered screens and cured. | 2016-03-10 |
20160067367 | SWITCHABLE GAS AND LIQUID RELEASE AND DELIVERY DEVICES, SYSTEMS, AND METHODS - Methods, systems, and devices are disclosed for implementing switchable dispensing and/or delivery of scented substances. In one aspect, a device includes a cartridge structured to include one or more chambers containing one or more scented substances contained in a corresponding chamber, a housing structured to include a compartment to hold the cartridge, an opening to allow the scented substances to dispense to an outer environment from the device, and one or more transporting channels formed between the compartment and the opening, in which each of the one or more transporting channels is configured to accelerate a scented substance from the corresponding chamber to the opening, and an actuator switch arranged in a corresponding transporting channel and operable to move between an open position and a closed position based on an applied signal to selectively allow passage of the scented substance from the corresponding transporting path. | 2016-03-10 |
20160067368 | NEBULIZER SYSTEM FOR FRESHENING THE AIR - Nebulizer systems to generate a mist of micro-droplets of a liquid for the purpose of freshening the atmosphere. Nebulizer systems having a small size that can be mounted on a sales stall to humidify and freshen fresh products displayed for sale, or in a vehicle to humidify and freshen the air and make it pleasant to breathe. | 2016-03-10 |
20160067369 | Cancer protection device - A natural base Himalayan Salt ionizer, which neutralizes and inhibits hazardous Electromagnetic field radiations EMF from our surrounding atmosphere. EMF is one of the biggest sources of Cancer cell growth and Melatonin loss. Himalayan salt has 84 essential minerals and trace elements, which support our body and respiratory system to breathe fresh air in any environment to improve our health quality. It reduces and inhibits many illnesses such as Asthma, Insomnia, migraines and headaches, allergies, dust particles, bacteria, fungus and pollutant etc. etc. . . . It also increases immunity, maintain normal blood pressure, enhances blood flow, reduces stress, depression and also enhances sexual abilities, so every time when heater turns on, the heating lights o PTC heating element gets hot, It produces heat which touches to the Salt rock crystals and it emits and produces negative ions. which bond with positive ions via ionization, neutralizing excess EMFs in the surrounding environment. Negative ions are beneficial for us because it neutralizes positive harmful ions EMF. EMF come through different sources e.g Cell phones, TV, Computers, Microwave ovens and many others electrical and mechanical devices. Natural Himalayan salt heaters/Air conditioners have ability to neutralize and purify the polluted air by increasing negative ions, which bond with positive ions via ionization, neutralizing excess EMFs in the surrounding environment. Simply put, the heat of the PTC heating elements or light warms the salt, which attracts humidity and creates a buildup of negative ions. Excessive positive ions bond with these negative ions (ionization), neutralizing the EMF waves in the atmosphere. | 2016-03-10 |
20160067370 | CARBOXYLMETHYL CELLULOSE FOAM FOR HEMOSTASIS AND WOUND TREATMENT, AND METHOD FOR PREPARING SAME - The present invention relates to a highly liquid absorbent and hardly water-soluble carboxymethyl cellulose (CMC) foam, which absorbs body fluid or water, expands in volume when absorbing liquid, does not gelate, and maintains shape. The hardly water-soluble CMC foam prepared according to the preparation method of the present invention has remarkably superior liquid absorption property, shows large volume expansibility when absorbing liquid, does not gelate, and maintains shape. Therefore, a remarkably improved ability is shown when used as a hemostatic agent and a wound dressing. In addition, when the CMC foam is treated with a CMC powder dispersing liquid, the surface characteristics change, thereby preventing adhesion with the skin and improving liquid retention capability. Thus, it is possible to control the liquid absorption property thereof to meet the desired purpose. | 2016-03-10 |
20160067371 | FIBRINOGEN-BASED TISSUE ADHESIVE PATCHES - A novel fibrinogen-based tissue adhesive patch is disclosed. The patch comprises a backing made from a non-permeable biocompatible polymer film into which a fibrinogen-based sealant is incorporated. In preferred embodiments of the invention, the fibrinogen-based sealant comprises fibrinogen, thrombin, and CaCl | 2016-03-10 |
20160067372 | MEDICAL CONSTRUCTS OF TWISTED LENGTHS OF COLLAGEN FIBERS AND METHODS OF MAKING SAME - Medical constructs with twisted cables formed from a plurality of collagen fibers twisted together to form strands and those strands twisted together to form cables and relate methods of twisting the collagen fibers to form the medical constructs while holding the fibers and strands of fibers in tension and twisting in a first direction (i.e., in a clockwise direction), then twisting them in a second opposing (counterclockwise) direction for a number of twists per inch. | 2016-03-10 |
20160067374 | COMPOSITE PROSTHETIC DEVICES - The present disclosure provides composite prosthetic devices comprising two or more layers of electrospun polymers and methods of preparation thereof. In some embodiments, the two or more layers can be porous and in other embodiments, one or more components is nonporous. The composite prosthetic devices can comprise various materials and the properties of the prosthetic devices can be tailored for use in a range of different applications. | 2016-03-10 |
20160067375 | 3D BIOMIMETIC, BI-PHASIC KEY FEATURED SCAFFOLD FOR OSTEOCHONDRAL REPAIR - This invention describes methods for the creation of 3D biologically inspired tissue engineered scaffolds with both excellent interfacial mechanical properties, and biocompatibility and products created using such methods. In some cases, a combination of nanomaterials, nano/microfabrication methods and 3D printing can be employed to create structures that promote tissue reconstruction and/or production. In other embodiments, electrospinning techniques can be used to create structures made of polymers and nanotubes. | 2016-03-10 |
20160067376 | BONE SUBSTITUTE NANOCOMPOSITES AND METHODS OF SYNTHESIS USING MULTIPHOSPHORYLATED PEPTIDES - The invention relates to peptides including DEDE(SSD) | 2016-03-10 |
20160067377 | Stem Cell Seeded Natural Substrates and Methods Relating Thereto - This disclosure provides compositions for treating tissue injuries comprising a tissue-derived substrate and mesenchymal stem cells adhered thereto, as well as methods of making and using such compositions. The tissue-derived substrates include bone, cartilage, and collagen matrix. | 2016-03-10 |
20160067378 | DECELLULARIZATION AND RECELLULARIZATION OF WHOLE ORGANS - The present invention provides systems and methods for the decellularization and recellularization of tissue segments. In certain instances the invention comprises coating or sealing decellularized tissue segments with a cross-linked alginate hydrogel. The present invention also provides a decellularization kit, which may be used to generate decellularized tissue segments for high throughput studies. Also included are compositions and methods of tissue sealants comprising methacrylated alginate. | 2016-03-10 |
20160067379 | EXTRACELLULAR MATRIX FOR THE TREATMENT OF INTESTINAL DISEASE AND METHODS THEREOF - A matrix, including epithelial basement membrane, for inducing repair of mammalian tissue defects and in vitro cell propagation derived from epithelial tissues of a warm-blooded vertebrate. | 2016-03-10 |
20160067380 | ENCAPSULATION OF PANCREATIC CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS - The present invention relates to methods for encapsulating pancreatic progenitors in a biocompatible semi-permeable encapsulating device. The present invention also relates to production of human insulin in a mammal in response to glucose stimulation. | 2016-03-10 |
20160067381 | CERAMIC BONE SUBSTITUTE MATERIAL AND METHOD FOR THE PRODUCTION THEREOF - A method for producing a ceramic osseoconductive bone substitute material, the bone substitute material, intervertebral disk implants containing the substitute bone material, and to methods of using the bone substitute material. | 2016-03-10 |
20160067382 | Osteoinductive Calcium Phosphates - The invention relates to a porous osteoinductive calcium phosphate material having an average grain size in a range of 0.1-1.50 μm, having a porosity consisting essentially only of micropores in a size range of 0.1-1.50 μm, and having a surface area percentage of micropores in a range of 10-40%. | 2016-03-10 |
20160067383 | AGENT FOR REGENERATING TYMPANIC MEMBRANE OR EXTERNAL AUDITORY CANAL - Provided is a tympanic membrane or ear canal regeneration agent comprising a combination of a gelatin sponge that carries basic fibroblast growth factor (bFGF) and a covering material. The covering material is used not only to fix the gelatin sponge to the affected portion, but also for the purpose of preventing drying and infections to provide a culturing environment that is favorable for regenerating tissue isolated from the outside. To promote tissue regeneration, the margin of the tympanic membrane or ear canal defect is preferably freshened in advance. | 2016-03-10 |
20160067384 | CATHETER SHAFT HAVING HIGH STRENGTH AND FLEXIBILITY - Elongated shaft for a catheter including a single layer biaxially oriented nonporous thermoplastic polymer tubular member having a Shore durometer hardness of less than about 75D is provided. Elongated shaft for a catheter prepared by a process is also provided. | 2016-03-10 |
20160067385 | Coatings for Controlled Release of Highly Water Soluble Drugs - The present disclosure relates to a multilayer coatings that include a hydrophobic encasing layer and allow controlled release of a water soluble drug. The encasing layer encases water soluble, or hydrophilic, drugs with a flexible layer and comes in good intimate contact with the water soluble drug layer. Thus, the encasing layer conforms to the water soluble drug and can control the release of the drug. Advantageously, major cuts or fissures in the coating do not cause the water soluble drug to leak or burst out; rather, the encasing layer continues to provide modulated release of the drug. The present disclosure also includes methods of making the coating, methods of using the coating, and articles that include the coating. | 2016-03-10 |
20160067386 | DEVICE AND METHOD TO FACILITATE SAFE, ADHESION-FREE SURGICAL CLOSURES - Surgical devices and methods are provided for preventing the formation of post-operative adhesions. In one device, an envelope of material defines at least one opening, and another layer of adhesion- preventing material is disposed on an exterior surface of the envelope. A rigid or semi-rigid barrier member is at least partially disposed in a space inside the envelope, without adhering to the envelope such that the barrier member can be pulled out of the envelope through the opening. | 2016-03-10 |
20160067387 | Amorphous Silicon Oxide, Amorphous Silicon Oxynitride, and Amorphous Silicon Nitride Thin Films and Uses Thereof - Amorphous SiOx (SiO2), SiONx, silicon nitride (Si3N4), surface treatments are provided, on both metal (titanium) and non-metal surfaces. Amorphous silicon-film surface treatments are shown to enhance osteoblast and osteoblast progenitor cell bioactivity, including biomineral formation and osteogenic gene panel expression, as well as enhanced surface hydroxyapatite (HA) formation. A mineralized tissue interface is provided using the amorphous silicon-based surface treatments in the presence of osteoblasts, and provides improved bone cell generation/repair and improved interface for secure attachment/bonding to bone. Methods for providing PEVCD-based silicon overlays onto surfaces are provided. Methods of increasing antioxidant enzyme (e.g., superoxide dismutase) expression at a treated surface for enhanced healing are also provided. Continuous generation and release of Si4+ ion into an in vitro or in vivo environment in the presence of osteoblasts/osteoblast progenitor cells, methods of employing same for enhancing the rate of bone healing/bone regeneration, is also described. | 2016-03-10 |
20160067388 | SURFACE TREATMENTS FOR VASCULAR STENTS AND METHODS THEREOF - Surface modified medical devices with nanotubes and polyelectrolyte multilayers, methods of promoting endothelialization, and methods of modifying a medical device surface are disclosed. Nanotubes may be formed on the surface of the medical device and may further be coated with polyelectrolyte multilayers of a polycation and a polyanion. The surface modification is characterized by a nanopattern on the surface of the medical device, with biomimetic properties. | 2016-03-10 |
20160067389 | BIODEGRADABLE ENDOPROSTHESES AND METHODS FOR THEIR FABRICATION - Biodegradable endoprostheses are formed from amorphous polymers having desirable biodegradation characteristics. The strength of such amorphous polymers is enhanced by annealing to increase crystallinity without substantially increasing the biodegradation time. | 2016-03-10 |
20160067390 | METHODS FOR IN VIVO AND IN VITRO USE OF GRAPHENE AND OTHER TWO-DIMENSIONAL MATERIALS - Two-dimensional materials, particularly graphene-based materials, having a plurality of apertures thereon can be formed into enclosures for various substances and introduced to an environment, particularly a biological environment (in vivo or in vitro). One or more selected substances can be released into the environment, one or more selected substances from the environment can enter the enclosure, one or more selected substances from the environment can be prevented from entering the enclosure, one or more selected substances can be retained within the enclosure, or combinations thereof. The enclosure can for example allow a sense-response paradigm to be realized. The enclosure can for example provide immunoisolation for materials, such as living cells, retained therein. | 2016-03-10 |
20160067391 | TRANSCUTANEOUS DEVICE FOR REMOVAL OF FLUID FROM A BODY - A single step body insertion device comprises a cannula and a Veress needle which penetrates the skin surface and relevant tissue layers to reach fluid and/or gases that need to be removed from the body. The cannula shaft and tapered tip are of a polymeric material which is flexible and kink resistant. The Veress needle has an engagement feature for engagement with the tapered tip of the cannula for delivery of the cannula into the body as the Veress needle is inserted into the body. The device is used for the management of conditions such as pneumothoraxes and pleural effusions as well as other conditions that require release of fluid and/or gas from the body. | 2016-03-10 |
20160067392 | THERAPY APPARATUS WITH INTEGRATED FLUID CONDUCTORS AND NOISE ATTENUATION - In one example embodiment, an apparatus may include a panel with integrated fluid channels, wherein the panel and the fluid channel consist only of surfaces that can be manufactured with a straight-pull mold. A port may also be integrated into the panel to facilitate coupling the fluid channel to pneumatic components in an assembly. A seal may be secured to the panel over the fluid channel to form an integrated fluid conductor. The seal is preferably an adhesive label that can also be used for product labeling. Such an apparatus may be used in a control unit of a therapy system, employing several integrated fluid conductors. A method of manufacturing may include molding a panel, wherein the mold forms a channel integral to the panel. The panel and the channel preferably consist of surfaces that can be molded with a straight-pull mold. | 2016-03-10 |
20160067393 | SYSTEM AND METHOD OF USE FOR A CONCEALABLE AND REDUCED NOISE BREAST PUMP - A system and method of use for a concealable breast pump is disclosed herein. The concealable and reduced noise breast pump generally is comprised of a breast shield member, a diaphragm member, a fluid capture member, a power supply member, a motor member, a pump member, and connection tube members. In an embodiment, the connection tube members join the breast shield member, the diaphragm member, and the pump member to each other. In another embodiment the concealable and reduced noise breast pump is further comprised of belt to be worn around the waist of a user of the system which allows certain members such as the diaphragm member, the fluid capture member, the power supply member, the motor member, and/or the pump members to be releasably connected to the belt member. In yet another embodiment, the system is further comprised of noise dampening members, which cover certain members of the system to reduce the noise level heard from the system. | 2016-03-10 |
20160067394 | CASSETTE MODULE HAVING AN INTEGRATED CENTRIFUGAL PUMP UNIT - The invention relates to a cassette module for processing blood and therapeutic fluids in an extracorporeal blood treatment, dialysis or infusion technology, comprising a base body ( | 2016-03-10 |
20160067395 | Devices, Systems, and Methods for Implanting and Using a Connector in a Tissue Wall - Embodiments of the present invention provide devices, systems, and methods for implanting and using a connector in a tissue wall to establish, maintain, control, and close a fluid communication between opposing surfaces of the tissue wall. The connector may include an anchoring device, a port, and a coupler device. The anchoring device may be configured for advancing at least partially through the tissue wall. The port may be positioned about a proximal end of the anchoring device, and the port may define an aperture therethrough. The coupler device may be positioned about a proximal end of the port, and the coupler device may be configured for coupling to a medical device. | 2016-03-10 |
20160067396 | TRANSCUTANEOUS POWER TRANSMISSION UTILIZING NON-PLANAR RESONATORS - A system for omni-orientational wireless energy transfer is described. A transmitter unit has a transmitter resonator with a coil that is configured to be coupled to a power supply to wirelessly transmit power to a receiver unit. A receiver unit has a receiver resonator with a coil coupled to a device load. At least one of the resonators is a non-planar resonator that spans a non-degenerate two-dimensional surface having at least one concave portion. | 2016-03-10 |
20160067397 | METHOD OF DETERMINING THE PRESSURE IN AN EXTRACORPOREAL CIRCUIT - The present invention relates to a method of determining the pressure or of a parameter correlated with the pressure in an extracorporeal circuit of a blood treatment apparatus, in particular of a dialyzer, wherein at least one blood pump which is driven by at least one motor is located in the blood circuit, wherein the motor current of the named motor and the blood flow or a parameter correlated therewith is measured for determining the pressure or the parameter correlated therewith and wherein the pressure p or the parameter correlated therewith is calculated from the measured values. | 2016-03-10 |
20160067398 | METHOD OF ULTRASONIC DEGASSING OF LIQUIDS FOR DIALYSIS - The invention relates to a device for degassing liquids, in particular liquids used in dialysis. Liquids to be degassed are treated by ultrasound in a degassing unit and are discharged from the degassing unit through a hollow channel in the ultrasonic sonotrode for further use. | 2016-03-10 |
20160067399 | DRAIN AND FILL LOGIC FOR AUTOMATED PERITONEAL DIALYSIS - A system for performing a peritoneal dialysis therapy includes at least one dialysis fluid pump, and a control unit operable with the at least one dialysis fluid pump to perform a plurality of peritoneal dialysis cycles, the cycles including a fill phase, a dwell phase and a drain phase. The control unit configured to (i) store a previously entered continuous cycling peritoneal dialysis (“CCPD”) therapy having a total prescribed fresh dialysate fill volume delivered over n cycles, the cycles performed over a total therapy duration, and (ii) automatically convert the CCPD therapy into a tidal peritoneal dialysis therapy having n+1 cycles, less a number of cycles already completed during the CCPD therapy, using the total prescribed fresh dialysis fill volume, and maintaining the total therapy duration. | 2016-03-10 |
20160067400 | FILLING AND RECIRCULATION DEVICE FOR A LIQUID SYSTEM OF AN EXTRACORPOREAL BLOOD TREATMENT DEVICE - Disclosed is a filling and recirculation device of a fluid conducting system for blood treatment which has a fluid connector and a three-dimensional four-way valve with a first valve plane on which an inlet connector for the fluid container, an arterial line connector, and a valve-internal coupling connector are arranged and a second valve plane on which an outlet connector and a venous line connector are arranged. The venous line connector is permanently connected with the valve-internal coupling connector. A manually operable valve rotary piston of the four-way valve has a first control section assigned to the first valve plane and a second control section assigned to the second valve plane. | 2016-03-10 |
20160067401 | MEDICAL/SURGICAL LAVAGE UNIT WITH A HANDPIECE HAVING A BARREL THAT CAN BE PIVOTED RELATIVE TO THE HANDGRP - A lavage unit with a handpiece that includes a handgrip and a barrel. The angular orientation of the barrel relative to the handgrip can be selectively set. The handpiece can thus take the form of a pistol-shaped tool, a wand or an intermediate shape between a pistol and a wand. | 2016-03-10 |
20160067402 | MEDICAL IMAGING APPARATUS AND CONTROLLING METHOD THEREOF - Disclosed herein are a medical imaging apparatus including a scanner configured to scan an object, an image generator configured to generate a monitoring image to monitor variations in brightness of a region of interest (ROI) of the object, a controller configured to determine a peak of brightness in the monitoring image, and a user interface configured to display the monitoring image and an indicator of the determined peak, and a method of controlling the same. According to the medical imaging apparatus and the method of controlling the same, over-injection of a contrast agent into the object may be prevented while a medical image is acquired, and an image may be obtained when the contrast agent is in an optimum state in consideration of various environmental factors. Accordingly, lesions and diseases may be more accurately determined and interpreted by using the medical image. | 2016-03-10 |